Table S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Yiyu Dong(Memorial Sloan Kettering Cancer Center), Ian Ganly(Memorial Sloan Kettering Cancer Center), Rui Qu(Suzhou Municipal Hospital), Bin Xu(Memorial Sloan Kettering Cancer Center), Yongxing Gong(Memorial Sloan Kettering Cancer Center), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Vladimir Makarov, Eric J. Sherman, Timothy A. Chan(Cleveland Clinic), James A. Fagin(Memorial Sloan Kettering Cancer Center), Ed Reznik(Icahn School of Medicine at Mount Sinai), Ronald Ghossein(Memorial Sloan Kettering Cancer Center), Fengshen Kuo(Memorial Sloan Kettering Cancer Center), Huiyong Zhao, Ömer Aras(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k